T1	p 66 117	adults with autistic disorder . BACKGROUND Autistic
T2	p 379 400	persons with autism .
T3	p 508 564	Thirty adults with autistic disorder completed a 12-week
T4	p 1562 1579	autistic disorder
T5	p 1583 1591	adults .
T6	p 1703 1741	children and adolescents with autism .
T7	i 23 41	placebo-controlled
T8	i 51 62	fluvoxamine
T9	i 580 598	placebo-controlled
T10	i 650 681	inhibitor fluvoxamine maleate .
T11	i 907 914	placebo
T12	i 936 947	Fluvoxamine
T13	i 964 971	placebo
T14	i 1355 1366	fluvoxamine
T15	i 1472 1483	Fluvoxamine
T16	i 1507 1514	placebo
T17	i 1614 1625	fluvoxamine
T18	o 431 435	safe
T19	o 682 700	Behavioral ratings
T20	o 984 1018	repetitive thoughts and behavior (
T21	o 1032 1052	maladaptive behavior
T22	o 1072 1082	aggression
T23	o 1119 1148	aspects of social relatedness
T24	o 1174 1182	language
T25	o 1214 1222	response
T26	o 1294 1296	IQ
T27	o 1310 1334	mild sedation and nausea
T28	o 1376 1448	tolerated . No dyskinesias , adverse cardiovascular events , or seizures